Diffuse Astrocytic and Oligodendroglial Tumors in Adults
Key Points
Key Points
- Each year, more than 15,000 people in the United States are newly diagnosed with diffuse astrocytic and oligodendroglial tumors, including glioblastoma.
- Recently, several systemic agents and a device have demonstrated improvements in survival when added to surgical and radiation therapies.
- Genetic alterations, specifically Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2), have become critical classification and prognostic biomarkers.
Treatment
...Treatment...
...IDH-mutant As...
...Oligodendroglioma...
...1.1People with oligodendroglioma,...
...is a reasonable alternative to PCV when toxi...
...tion 1.2Within the group of people with oligodendr...
...Ol...
...mendation 1.3People with oligodendrogl...
Temozolomide is a reasonable alternative t...
...Astroc...
...n 1.4People with astrocytoma, IDH-mutant, 1p/19q...
...1.5In astrocytoma, IDH-mutant, 1p/1...
...Astrocytoma, IDH-muta...
...ecommendation 1.6People with astrocytoma,...
...Astrocytoma...
...commendation 1.7People with astrocy...
...Glioblastoma and Other ID...
Recommendation 2.1People with astrocytomas, IDH-w...
...endation 2.2Concurrent temozolomide and radia...
...on 2.3Six months of adjuvant temozolomide shoul...
Recommendation 2.4Alternating electric fi...
...endation 2.5Bevacizumab is NOT rec...
...on 2.6In people with glioblastoma, IDH-wi...
...n 2.7In people with glioblastoma, IDH-wildtype, C...
...mendation 2.8No recommendation for or against any...
...recurrent glioblastoma should be referred for p...
...tion 2.9No recommendation for or against an...
...diffuse midline glioma should be referred for...
Table 1. Reasonable Doses and Schedules by Recommendation
...sonable Doses and Schedules by Rec...